basmisanil basmisanil basmisanil (inn; developmental codes rg-1662 and ro5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing gabaa receptors which is under development by roche for the treatment of cognitive impairment associated with down syndrome. as of june 2016, it is no longer studied. it is studied with schizophrenia patients. basmisanilclinical dataother namesrg-1662; ro5186582atc codenoneidentifiers iupac name (1,1-dioxo-1,4-thiazinan-4-yl)-methoxy]pyridin-3-yl]methanone cas number1159600-41-5pubchem cid57336276chemspider34500832unii788pet5suakeggd10863 ychemical and physical dataformulac21h20fn3o5smolar mass445.47 g·mol−13d model (jsmol)interactive image smiles cc1=c(c(=no1)c2=cc=c(c=c2)f)coc3=nc=c(c=c3)c(=o)n4ccs(=o)(=o)cc4 inchi inchi=1s/c21h20fn3o5s/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12h,8-11,13h2,1h3key:vcgrfbxvsfagga-uhfffaoysa-n